Frankfurt - Delayed Quote EUR

Atossa Therapeutics, Inc. (YAG2.F)

Compare
0.8510
+0.1510
+(21.57%)
At close: January 31 at 2:07:53 PM GMT+1
Currency in EUR All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Operating Expense
29,489.0000
--
27,691.0000
20,521.0000
14,607.0000
Operating Income
-29,489.0000
--
-27,691.0000
-20,521.0000
-14,607.0000
Net Non Operating Interest Income Expense
4,449.0000
--
877.0000
6.0000
-938.7940
Other Income Expense
-1,871.0000
--
-146.0000
-91.0000
-3,221.0000
Pretax Income
-26,911.0000
--
-26,960.0000
-20,606.0000
-17,828.0000
Net Income Common Stockholders
-26,911.0000
--
-26,960.0000
-20,606.0000
-22,331.0000
Diluted NI Available to Com Stockholders
-26,911.0000
--
-26,960.0000
-20,606.0000
-22,331.0000
Basic EPS
-0.21
-0.24
-0.21
-0.18
-1.97
Diluted EPS
-0.21
-0.24
-0.21
-0.18
-1.97
Basic Average Shares
125,530.4760
126,081.6020
126,624.0000
116,950.0000
11,309.0000
Diluted Average Shares
125,530.4760
126,081.6020
126,624.0000
116,950.0000
11,309.0000
Total Operating Income as Reported
-29,489.0000
--
-27,691.0000
-20,521.0000
-14,607.0000
Total Expenses
29,489.0000
--
27,691.0000
20,521.0000
14,607.0000
Net Income from Continuing & Discontinued Operation
-26,911.0000
--
-26,960.0000
-20,606.0000
-17,828.0000
Normalized Income
-25,201.0000
--
-26,960.0000
-20,606.0000
-14,556.0000
Interest Income
4,449.0000
--
877.0000
6.0000
--
Net Interest Income
4,449.0000
--
877.0000
6.0000
-938.7940
EBIT
-29,489.0000
--
-27,691.0000
-20,521.0000
-14,607.0000
EBITDA
-29,462.0000
--
-27,683.0000
-20,498.0000
-14,560.0000
Reconciled Depreciation
27.0000
--
8.0000
23.0000
47.0000
Net Income from Continuing Operation Net Minority Interest
-26,911.0000
--
-26,960.0000
-20,606.0000
-17,828.0000
Total Unusual Items Excluding Goodwill
-1,710.0000
--
--
--
-3,272.0000
Total Unusual Items
-1,710.0000
--
--
--
-3,272.0000
Normalized EBITDA
-27,752.0000
--
-27,683.0000
-20,498.0000
-11,288.0000
12/31/2020 - 3/27/2013

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

W2J.F Carisma Therapeutics, Inc.
0.5940
0.00%
 
2X10.F ABIVAX Société Anonyme
5.55
+0.91%
 
BX2.F BioXcel Therapeutics, Inc.
0.3289
+10.00%
 
PSH.F Sernova Corp.
0.1363
+0.22%
 
W1H.F Onco-Innovations Limited
1.3300
+2.31%
 
IFRX InflaRx N.V.
2.4100
+1.69%
 
CARM Carisma Therapeutics, Inc.
0.4598
-7.86%
 
HEPA Hepion Pharmaceuticals, Inc.
0.1795
-3.80%
 
PPCB Propanc Biopharma, Inc.
9.00
0.00%
 
DWTX Dogwood Therapeutics, Inc.
12.49
-2.12%